Current understanding of allergic fungal rhinosinusitis and treatment implications

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 22, Issue 3, 2014, Pages 221-226

  Plonk, Drew P ^a   Luong, Amber ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Allergic fungal rhinosinusitis; chronic rhinosinusitis with nasal polyposis; cytokines; management; pathophysiology

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; CORTICOSTEROID; FUNGUS ANTIGEN; INTERLEUKIN 25; INTERLEUKIN 33; THYMIC STROMAL LYMPHOPOIETIN;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ALLERGIC FUNGAL RHINOSINUSITIS; ANTIMICROBIAL THERAPY; BIPOLARIS; CHRONIC RHINOSINUSITIS; CORTICOSTEROID THERAPY; EPITHELIUM CELL; FUNGAL SINUSITIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; NOSE POLYP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; STAPHYLOCOCCUS AUREUS; TH2 CELL; IMMUNOLOGY; MYCOSES; RHINITIS, ALLERGIC; SINUSITIS;

HUMANS; MYCOSES; RHINITIS, ALLERGIC; SINUSITIS;

EID: 84900421892     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0000000000000043     Document Type: Review

References (51)

1. Katzenstein A, Greenberger P, Sale S. Allergic aspergillus sinusitis: a newly recognized form of sinusitis. J Allergy Clin Immunol 1983; 72:89-93
2. Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis, and management. Med Mycol 2009; 47 (Suppl 1):S324-S330
3. Ferguson BJ, Barnes L, Bernstein JM, et al. Geographic variation in allergic fungal rhinosinusitis. OtoLaryngol Clin North Am 2000; 33:441-449
4. Marple BF. Allergic fungal rhinosinusitis: current theories and management strategies. Laryngoscope 2001; 111:1006-1019
5. Agarwal G, Citardi MJ, Fakhri S, Luong A. Allergic fungal rhinosinusitis. In: Kountakis SE, editor. Encyclopedia of otoLaryngology, head and neck surgery, 1st ed. New York: Springer; 2013
6. Bent JP 3rd, Kuhn FA. Diagnosis of allergic fungal sinusitis. OtoLaryngol Head Neck Surg 1994; 111:580-588
7. Manning SC, Holman M. Further evidence for allergic pathophysiology in allergic fungal sinusitis. Laryngoscope 1998; 108:1485-1496
8. CAllejas CA, DougLAs RG. Fungal rhinosinusitis: what every allergist should know. Clin Exp Allergy 2013; 43:835-849
9. Bachert C, Gevaert P, Holtappels G, et al. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000; 14:279-290
10. Bachert C, Gevaert P, Holtappels G, et al. Mediators in nasal polyposis. Curr Allergy Asthma Rep 2002; 2:481-487
11. Luong A, Davis LS, Marple BF. Peripheral blood mononuclear cells from allergic fungal rhinosinusitis adults express Th2 cytokine response to fungal antigens. Am J Rhinol 2009; 23:281-287
12. Porter P, SusarLA SC, Poli kepahad S, et al. Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi. Mucosal Immunol 2009; 2:504-517
13. Ferguson BJ, Seethala R, Wood W A. Eosinophilic bacterial chronic rhinosinusitis. Laryngoscope 2007; 117:2036-2040
14. CLark DW, Wenaas A, Luong A, et al. Staphylococcus aureus prevalence in allergic fungal rhinosinusitis vs other subsets of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2013; 3:89-93
15. Dutre T, Al Dousary S, Zhang N, Bachert C. Allergic fungal rhinosinusitis: more than a fungal disease J Allergy Clin Immunol 2013; 132:487-489
16. Bachert C, van Steen K, Zhang N, et al. Specific IgE Staphylococcus aureus enterotoxins: an independent risk factor for asthM.A. J Allergy Clin Immunol 2012; 130:376-381
17. Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracelluLar ATP, is a sensor for an airborne allergen and triggers IL-33 release and innat e Th2-type responses. J Immunol 2011; 186:4375-4387.
18. Bernink J Mjosberg J Spits H., Th1-and Th2-like subsets of innate lymphoid cells. Immunol Rev, 2013,252, 133-138.
19. . Shaw JL, Fakhri S, Citardi MJ, et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med 2013; 188:432-439
20. Mjö sberg JM, Trifari S, Crellin NK, et al. Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12:1055-1062
21. Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2013; 132:593-600
22. Shaw JL, Ashoori F, Fakhri S, et al. Increased percentage of mast cells within sinonasal mucosa of chronic rhinosinusitis with nasal polyp patients independent of atopy. Int Forum Allergy Rhinol 2012; 2:233-240
23. Ayers CM, Schlosser RJ, O ?Connell BP, et al. Increased presence of dendritic cells and dendritic cell chemokines in the sinus mucosa of chronic rhinosinusitis with nasal polyps and allergic fungal rhinosinusitis. Int Forum Allergy Rhinol 2011; 1:296-302
24. Nakayama T, Yoshikawa M, Asaka D, et al. Mucosal eosinophilia and recurrence of nasal polyps: new cLAssifiCAtion of chronic rhinosinusitis. Rhinology 2011; 49:392-396
25. Mulligan JK, White DR, Wang EW, et al. Vitamin D3 deficiency increases sinus mucosa dendritic cells in pediatric chronic rhinosinusitis with nasal polyps. OtoLaryngol Head Neck Surg 2012; 147:773-781
26. Stewart AE, Hunsaker DH. Fungus-specific IgG and IgE in allergic fungal rhinosinusitis. OtoLaryngol Head Neck Surg 2002; 127:324-332
27. Wise SK, Ahn CN, Lathers DM, et al. Antigen-specific IgE in sinus mucosa of allergic fungal rhinosinusitis patients. Am J Rhinol 2008; 22:451-456
28. Wright ED , Agrawal S. Impact of perioperative systemic steroids on surgiCAl outcomes in patients with chronic rhinosinusitis with polyposis: evaluation with the novel Perioperative Sinus Endoscopy (POSE) scoring system. Laryngoscope 2007; 117 (Suppl 15):1-28
29. Bent JP 3rd, Kuhn FA. Allergic fungal sinusitis /polyposis. Allergy Asthma Proc 1996; 17:259-268
30. Schubert MS, Goetz DW. Evaluation and treatment of allergic fungal sinusitis. II. Treatment and follow-up. J Allergy Clin Immunol 1998; 102:395-402
31. Kuhn FA, Javer AR. Allergic fungal rhinosinusitis: perioperative management, prevention of recurrence, and role of steroids and antifungal agents. OtoLaryngol Clin North Am 2000; 33:419-433
32. Rupa V, Jacob M, Mathews MS, Seshadri MS. A prospective, randomized, pLacebo-controlled tr ial of postoperative oral steroid in allergic fungal sinusitis. Eur Arch OtorhinoLaryngol 2010; 267:233-238
33. Ikram M, Abbas A, Suhail A, et al. Management of allergic fungal sinusitis with postoperative oral and nasal steroids: a controlled study. Ear Nose Throat J 2009; 88:E8-11
34. Sachanandi NS, Piccirillo JF, Kramper MA, et al. The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis. Arch OtoLaryngol Head Neck Surg 2009; 135:303-307
35. Man LX, Farhood Z, Luong A, et al. The effect of intranasal flutiCAsone propionate irrigations on salivary cortisol, intraocuLar pressure, and posterior subCApsuLar CAtaracts in postsurgiCAl chronic rhinosinusitis patie nts. Int Forum Allergy Rhinol 2013; 3:953-957
36. Kalish L, Snidvongs K, Sivasubramaniam R, et al. TopiCAl steroids for nasal polyps. Cochrane Database Syst Rev 2012; 12:CD006549
37. Mabry RL, Mabry CS. Immunotherapy for allergic fungal sinusitis: the second year. OtoLaryngol Head Neck Sur 1997; 117:367-371
38. Mabry RL, Marple BF, Folker RJ, Mabry CS. Immunotherapy for allergic fungal sinusitis: three years? experience. OtoLaryngol Head Neck Surg 1998; 119:648-651
39. Mabry RL, Mabry CS. Allergic fungal sinusitis: the role of immunotherapy. OtoLaryngol Clin North Am 2000; 33:433-440.
40. Mabry RL Marple BF Mabry CS, Outcomes after discontinuing immunotherapy for allergic fungal sinusitis, OtoLaryngol Head Neck Surg,2000,122, 104-106.
41. Bassichis BA, Marple BF, Mabry RL, et al. Use of immunotherapy in previously treated patients with allergic fungal sinusitis. OtoLaryngol Head Neck Surg 2001; 125:487-490
42. Greenhaw B, deShazo RD, Arnold J, Wright L. Fungal immunotherapy in patients with allergic fungal sinusitis. Ann Allergy Asthma Immunol 2011; 107:432-436
43. Hall AG, deShazo RD. Immunotherapy for allergic fungal sinusitis. Curr Opin Allergy Clin Immunol 2012; 12:629-634
44. Shin SH, Ponikau JU, Sherris DA, et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airbone fungi. J Allergy Clin Immunol 2004; 114:1369-1375
45. Sacks PL, Harvey RJ, Rimmer J, et al. TopiCAl and systemic antifungal therapy for the symptomatic treatme nt of chronic rhinosinusitis. Cochrane Database Syst Rev 2011; 8:CD008263
46. Thanasumpun T, Batra PS. Oral antifungal therapy for chronic rhinosinusitis and its subtypes: a systematic review. Int Forum Allergy Rhinol 2011; 1:382-389
47. Le T, Psaltis A, Tan LW, Wormald PJ. The effiCAcy of topiCAl antibiofilm agents in a sheep model of rhinosinusitis. Am J Rhinol 2008; 22:560-567
48. Rudmik L, Hoy M, Schl osser RJ, et al. TopiCAl therapies in the management of chronic rhinosinusitis: an evidence-based review with recommendations. Int Forum Allergy Rhinol 2013; 3:281-288
49. Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, pLacebocontrolled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010; 48:318-324
50. CAin RB, LAl D. Update on the management of chronic rhinosinusitis. Infect Drug Resist 2013; 6:1-14
51. Gevaert P, Van Bruaene N, CAttaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a tre atment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128:989-995